|
| Press Releases |
|
 |
|
| Wednesday, June 28, 2017 |
|
|
Eisai Listed for 16th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment |
| Eisai Co., Ltd. announced today that it has been included in the FTSE4Good Index Series for the 16th consecutive year since its initial inclusion in 2002. more info >> |
|
| Tuesday, June 27, 2017 |
|
|
Eisai Temporarily Withdraws New Drug Application for Anticancer Agent Halaven in China |
| Eisai Co., Ltd. announced today that, in alignment with Chinese regulations, it has temporarily withdrawn its new drug application for anticancer agent eribulin mesylate (Brand name: Halaven) in China in order to submit additional documentation. more info >> |
|
| Friday, June 23, 2017 |
|
|
Eisai Submits Application for Additional Indication of Anticancer Agent Lenvima for Hepatocellular Carcinoma in Japan |
| Eisai Co., Ltd. announced today that it has submitted an application for an additional indication of its in-house discovered and developed anticancer agent Lenvima (generic name: lenvatinib mesylate) for the treatment of hepatocellular carcinoma (HCC) in Japan, the first in the world. more info >> |
|
|
Cardiovascular Outcomes Trial of Anti-Obesity Agent Lorcaserin to Continue Based on Recommendation of Independent Data Monitoring Committee After Completion of Interim Safety Analysis |
| Eisai Co., Ltd. has announced that it has received a recommendation from an independent Data Monitoring Committee to continue the ongoing Cardiovascular Outcomes Trial of lorcaserin hydrochloride after the completion of a pre-specified interim safety analysis, evaluating the incidence of Major Adverse Cardiovascular Events (MACE), defined as cardiovascular death, myocardial infarction or stroke. more info >> |
|
| Thursday, June 8, 2017 |
|
|
Launch of Pain Treatment Lyrica OD Tablet Formulation in Japan |
| Pfizer Japan Inc. and Eisai Co., Ltd. have announced that Lyrica OD Tablets 25mg, 75mg, 150mg (OD tablet: orally disintegrating tablet), a new formulation following pain treatment Lyrica Capsules (pregabalin). more info >> |
|
| Monday, June 5, 2017 |
|
|
Eisai to Present Results of Phase III Trial of Lenvima (Lenvatinib) as First-Line Treatment for Unresectable Hepatocellular Carcinoma in Oral Session at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that the results of a Phase III trial (Study 304) of its in-house discovered and developed anticancer agent lenvatinib mesylate against the comparator sorafenib as first-line treatment for unresectable hepatocellular carcinoma, will be orally presented during the 53rd Annual Meeting of ASCO. more info >> |
|
|
Eisai to Present Results of Phase Ib/II Study of Anticancer Agent Lenvima (Lenvatinib) in Combination With Anti-PD-1 Antibody Pembrolizumab |
| Eisai Co., Ltd. announced the first results for metastatic endometrial carcinoma obtained from a Phase Ib/II study (Study 111) of its in-house developed multi-kinase inhibitor lenvatinib mesylate in combination with the MSD anti-PD-1 antibody pembrolizumab (brand name: KEYTRUDA), during a presentation at the 53rd Annual Meeting of ASCO. more info >> |
|
| Thursday, June 1, 2017 |
|
|
Eisai Commits Funding to the 2nd Phase of Global Health Innovative Technology Fund Activities |
| Eisai Co., Ltd. has announced that it will grant a total of 500 million yen to the Global Health Innovative Technology Fund (GHIT Fund) to fund the second phase of its activities, which will take place in the five-year period from FY 2018 to FY 2022. more info >> |
|
| Wednesday, May 31, 2017 |
|
|
Eisai Enters Into a New Joint Research Agreement With the Broad Institute to Develop an Antimalarial Medicine |
| Eisai Co., Ltd. announced today that it has entered into a new joint research agreement with the Broad Institute, a collaborative research institute which includes researchers from the Massachusetts Institute of Technology and Harvard University to develop a new antimalarial medicine based on antimalarial drug targets the team identified last year. more info >> |
|
| Thursday, May 18, 2017 |
|
|
Eisai to Present Abstracts on Oncology Products and Pipeline at 53rd ASCO Annual Meeting |
| Eisai Co., Ltd. announced today that a series of abstracts highlighting new study results for its in-house discovered lenvatinib mesylate and eribulin mesylate, as well as H3B-8800 will be presented during the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO). more info >> |
|
|
|
|
|
|
|
|
 |
| Latest Press Releases |
|
Graphene Manufacturing Group Ltd. Announces Upsize of Bought Deal Public Offering for Gross Proceeds of C$6 Million
Aug 22, 2025 23:00 HKT/SGT
|
|
|
Ta Yang Group Holdings Limited Announcing AI Transformation Blueprint
Aug 22, 2025 19:21 HKT/SGT
|
|
|
CaoCao Inc. (2643.HK) Added to Hang Seng Composite Index, Set to Join Hong Kong Stock Connect on Sept 8
Aug 22, 2025 18:51 HKT/SGT
|
|
|
CITIC Resources Deepens Dual Driver Development Strategy of "Investment + Trading"
Aug 22, 2025 18:28 HKT/SGT
|
|
|
Everbright Grand China Achieved Revenue of RMB24.5 Million in 2025 1H
Aug 22, 2025 13:26 HKT/SGT
|
|
|
China International Development Corporation Limited announces strategic acquisition of 20% stake in NVT
Aug 22, 2025 08:22 HKT/SGT
|
|
|
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Successfully Carries Out Space Protein Crystallization Experiments 
Aug 22, 2025 3:00 JST
|
|
|
Asia's CX Leaders Are Aligning Strategy Around AI, Efficiency, and Workforce Engagement: Key Insights from Customer Experience Live Show Asia 2025
Aug 21, 2025 22:00 HKT/SGT
|
|
|
NEC digital technologies to empower small-scale producers in Africa in partnership with IFAD
Aug 21, 2025 20:32 JST
|
|
|
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and AAR Japan for Donation of Solar Modules to Kenya
Aug 21, 2025 20:15 JST
|
|
|
Aiming to Build Battery Ecosystem, Toyota and Mazda Start Tests of Energy Storage System Using Electrified Vehicle Batteries
Aug 21, 2025 19:50 JST
|
|
|
NEC signs Memorandum of Cooperation with the Senegalese government, CFPT-SJ, JICA, and four Japan-based companies for vocational training in Senegal
Aug 21, 2025 19:27 JST
|
|
|
Genes Tech Group Announces 2025 Interim Results, Total revenue increased by 9.40% YoY to approximately NTD585.31 million
Aug 21, 2025 18:22 HKT/SGT
|
|
|
Sharp Corporation and Sharp Energy Solutions Corporation Sign Memorandum of Understanding with Mitsui O.S.K. Lines, and IOM to Advance Cooperation through Renewable Energy
Aug 21, 2025 19:07 JST
|
|
|
Lepu Biopharma (2157.HK) announces 2025 interim results
Aug 21, 2025 14:38 HKT/SGT
|
|
|
|
|
More Press release >> |
|
|
|
|
|
|
|
